By Counterforce Health Team in Hemlibra (emicizumab-kxwh) —

How to Get Hemlibra (Emicizumab) Covered by UnitedHealthcare in Virginia: Complete PA Guide, Appeals, and Templates

Answer Box: Quick Path to Hemlibra Coverage in Virginia

UnitedHealthcare requires prior authorization for all Hemlibra (emicizumab-kxwh) prescriptions. For hemophilia A patients with factor VIII inhibitors ≥5 Bethesda units, there's no step therapy requirement. Submit PA through the UnitedHealthcare Provider Portal with complete clinical documentation including inhibitor titers, bleeding history, and weight-based dosing plan. Standard decisions take 14 days; urgent cases 72 hours. If denied, Virginia residents have strong appeal rights through the State Corporation Commission's external review process using Form 216-A.

First step today: Have your hematologist gather inhibitor lab results, bleeding logs, and prior treatment records for PA submission.

Table of Contents

Understanding UnitedHealthcare's Hemlibra Coverage

UnitedHealthcare covers Hemlibra (emicizumab-kxwh) for routine prophylaxis in hemophilia A patients, but all prescriptions require prior authorization through OptumRx. The good news for Virginia patients: UnitedHealthcare doesn't require step therapy for patients with factor VIII inhibitors, streamlining the approval process compared to some other specialty medications.

Coverage at a Glance

Requirement What It Means Where to Find It Source
Prior Authorization Required for all Hemlibra prescriptions UnitedHealthcare Provider Portal UHC PA Requirements
Step Therapy None for inhibitor patients UHC policy documents UHC Hemlibra Policy
Specialty Pharmacy Required via Optum Specialty Plan documents Verify with member services
Age Limits None specified FDA labeling FDA Prescribing Information
Diagnosis Codes D66 (Hemophilia A) ICD-10 manual Clinical documentation

Prior Authorization Requirements

UnitedHealthcare's approval criteria differ based on inhibitor status:

For Patients WITH Factor VIII Inhibitors (≥5 Bethesda Units)

  • Confirmed hemophilia A diagnosis (ICD-10: D66)
  • High-titer inhibitors (≥5 Bethesda units) documented by lab results
  • Prescribed for routine prophylaxis (not acute bleeding episodes)
  • Hematologist prescription required

For Patients WITHOUT Inhibitors

  • Confirmed hemophilia A diagnosis
  • Prescribed for routine prophylaxis only
  • Documentation that patient isn't established on therapy via free samples
  • Clinical rationale for choosing Hemlibra over standard factor VIII
Note: Authorization duration is typically 12 months initially, with 12-month reauthorizations upon documentation of positive clinical response.

Step-by-Step: Fastest Path to Approval

  1. Gather Clinical Documentation (Patient + Clinic)
    • Recent inhibitor titer results (Bethesda units)
    • Bleeding episode logs from past 12 months
    • Prior treatment records and outcomes
    • Weight for dosing calculations
    • Timeline: 1-3 days to compile
  2. Complete Medical Necessity Letter (Hematologist)
    • Use Genentech's template from Hemlibra HCP Resources
    • Include FDA labeling references for prophylaxis indication
    • Timeline: 1-2 business days
  3. Submit PA Request (Clinic Staff)
    • Primary method: UnitedHealthcare Provider Portal (Pharmacy PA section)
    • Alternative: Call 866-889-8054
    • Upload all supporting documents as PDFs
    • Timeline: Same day submission
  4. Track Application Status (Patient + Clinic)
    • Portal provides reference number for tracking
    • Standard decision: 14 days
    • Expedited/urgent: 72 hours
    • Timeline: Ongoing monitoring
  5. Prepare for Peer-to-Peer if Needed (Hematologist)
    • UnitedHealthcare may request physician discussion
    • Have clinical rationale and guidelines ready
    • Timeline: Within 48 hours of request
  6. Arrange Specialty Pharmacy (Patient)
    • Typically through Optum Specialty
    • Coordinate delivery and storage requirements
    • Timeline: 3-5 days after approval
  7. Plan Appeal Strategy if Denied (All Parties)
    • Virginia external review available through SCC
    • Strong success rate with proper documentation
    • Timeline: Begin immediately upon denial

Medical Necessity Letter Essentials

Your hematologist's medical necessity letter is crucial for approval. Based on successful appeals and Counterforce Health's experience with UnitedHealthcare denials, include these key elements:

Required Components

  • Patient Demographics: Full name, DOB, member ID, prescriber contact
  • Diagnosis Statement: "Patient has severe hemophilia A (ICD-10: D66) with high-titer factor VIII inhibitors (X Bethesda units as of [date])"
  • FDA Indication Reference: "Hemlibra is FDA-approved for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in patients with hemophilia A with or without factor VIII inhibitors"
  • Clinical Rationale: Bleeding frequency despite current therapy, failed alternatives, contraindications to other treatments
  • Treatment Plan: Weight-based dosing (typically 3 mg/kg weekly after loading), monitoring schedule, administration plan
  • Prescriber Attestation: Hematologist signature and direct contact for peer-to-peer review

Supporting Documentation to Attach

  • Lab results showing inhibitor titers
  • Bleeding episode logs
  • Prior treatment records
  • FDA prescribing information excerpt
  • Relevant clinical notes

Common Denial Reasons & How to Fix Them

Denial Reason How to Overturn Required Documents
"Not medically necessary" Emphasize prophylaxis indication, bleeding frequency Bleeding logs, FDA label excerpt
"Experimental/investigational" Reference FDA approval date (2017), established use FDA approval letter, peer-reviewed studies
"Missing clinical information" Provide complete inhibitor status, weight-based dosing Lab results, dosing calculations
"Step therapy not completed" Document inhibitor status (exempts from step therapy) Bethesda unit results ≥5
"Off-label use" Confirm prophylaxis (not acute treatment) indication Treatment plan, FDA labeling
From Our Advocates: We've seen UnitedHealthcare approvals turn around quickly when the medical necessity letter clearly distinguishes between prophylaxis (covered) and on-demand treatment (often denied). Including specific Bethesda unit measurements rather than just "high-titer inhibitors" strengthens the clinical picture significantly.

Appeals Process in Virginia

If UnitedHealthcare denies your Hemlibra prior authorization, Virginia offers robust appeal rights through multiple levels:

Internal Appeals (UnitedHealthcare)

  • First Level: 30 days to file from denial date
  • Second Level: Available if first level denied
  • Expedited: 72 hours for urgent medical needs
  • Submit via: Member portal, mail, or fax (check denial letter for specifics)

External Review (Virginia State Corporation Commission)

Virginia's external review process is particularly strong for specialty drug denials:

  • Eligibility: Available after completing UnitedHealthcare's internal appeals
  • Timeline: 120 days from final internal denial to request external review
  • Form Required: Form 216-A External Review Request (verify current link with SCC)
  • Decision Timeline: 45 days for standard review, 72 hours for expedited
  • Success Rate: High for properly documented medical necessity cases
  • Cost: Free to consumers

Contact Information

  • Virginia SCC Bureau of Insurance: (804) 371-9740
  • Email: [email protected]
  • Mailing Address: P.O. Box 1157, Richmond, VA 23218

The SCC's Independent Review Organizations include board-certified hematologists who understand complex bleeding disorders, making Virginia's external review particularly effective for Hemlibra cases.

Scripts & Templates

Patient Phone Script for UnitedHealthcare

"Hello, I'm calling about prior authorization status for Hemlibra, emicizumab-kxwh, for my hemophilia A with factor VIII inhibitors. My member ID is [number], and the PA reference number is [number]. Can you provide the current status and any additional information needed?"

Clinic Staff Peer-to-Peer Request Script

"I need to schedule a peer-to-peer review for a Hemlibra prior authorization denial. The patient has severe hemophilia A with documented high-titer inhibitors, and we have comprehensive clinical documentation supporting medical necessity for prophylaxis. When can Dr. [Name] speak with your medical director?"

Costs & Patient Assistance

Manufacturer Support

  • Genentech Access Solutions: Provides benefit verification, PA support, and copay assistance
  • Contact: Genentech Access Solutions
  • Copay Card: May reduce out-of-pocket costs for eligible commercially insured patients

Additional Resources

  • National Bleeding Disorders Foundation: Patient assistance and advocacy
  • Hemophilia Federation of America: Educational resources and support
  • Virginia Hemophilia Treatment Centers: Clinical and financial guidance

When Prior Authorization Appeals Are Needed

Counterforce Health helps patients, clinicians, and specialty pharmacies turn insurance denials into successful appeals by analyzing denial letters, plan policies, and clinical notes to create targeted, evidence-backed rebuttals. Their platform identifies specific denial reasons and drafts point-by-point responses aligned with each plan's own rules, pulling the right medical evidence and weaving it into appeals that meet procedural requirements while tracking deadlines and required documentation.

For Hemlibra denials specifically, success often depends on clearly documenting inhibitor status, bleeding frequency, and the prophylaxis indication while addressing any payer-specific coverage criteria that weren't initially met.

FAQ

How long does UnitedHealthcare prior authorization take for Hemlibra in Virginia? Standard decisions take up to 14 days, while urgent cases are processed within 72 hours. Submit through the UnitedHealthcare Provider Portal for fastest processing.

What if Hemlibra isn't on UnitedHealthcare's formulary? Hemlibra typically requires specialty pharmacy coverage through OptumRx. If non-formulary, request a formulary exception with your PA submission, emphasizing lack of therapeutic alternatives for inhibitor patients.

Can I request an expedited appeal if I'm having frequent bleeding episodes? Yes. Virginia allows expedited external review within 72 hours if your physician certifies that delays could seriously jeopardize your health. UnitedHealthcare also offers expedited internal appeals.

Does step therapy apply if I've tried factor VIII outside Virginia? No. UnitedHealthcare's policy exempts patients with factor VIII inhibitors ≥5 Bethesda units from step therapy requirements, regardless of where prior treatments occurred.

What happens if both internal appeals fail? Virginia's external review through the SCC offers an independent assessment by medical experts. The process is free, and decisions are binding on UnitedHealthcare.

How do I prove medical necessity for prophylaxis vs. on-demand treatment? Document regular bleeding episodes, failed prophylaxis attempts with other agents, and emphasize the FDA-approved prophylaxis indication. Avoid language suggesting acute or on-demand use.

Can family members help with the appeal process? Yes, but you'll need to complete an Authorized Representative form allowing them to act on your behalf. This form is available through UnitedHealthcare and the Virginia SCC.

What if I'm on Medicare Advantage through UnitedHealthcare? The same PA requirements apply, but appeal timelines may differ slightly. Medicare Advantage plans must follow federal appeal standards, which often provide additional consumer protections.

Sources & Further Reading

Disclaimer: This information is for educational purposes only and does not constitute medical or legal advice. Coverage policies and appeal procedures may change. Always verify current requirements with UnitedHealthcare and consult with your healthcare provider for medical decisions. For personalized assistance with insurance appeals, contact the Virginia State Corporation Commission Bureau of Insurance at (804) 371-9740.

Powered by Counterforce Health—AI that turns drug denials into evidence-based appeals patients and clinicians can submit today.